586 related articles for article (PubMed ID: 33670993)
1. TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.
Yeo J; Ko M; Lee DH; Park Y; Jin HS
Pharmaceuticals (Basel); 2021 Feb; 14(3):. PubMed ID: 33670993
[TBL] [Abstract][Full Text] [Related]
2. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade.
Yoo KJ; Johannes K; González LE; Patel A; Shuptrine CW; Opheim Z; Lenz K; Campbell K; Nguyen TA; Miriyala J; Smith C; McGuire A; Tsai YH; Rangwala F; de Silva S; Schreiber TH; Fromm G
J Immunol; 2022 Aug; 209(3):510-525. PubMed ID: 35817517
[TBL] [Abstract][Full Text] [Related]
3. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.
Chiang EY; Mellman I
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379739
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8
Banta KL; Xu X; Chitre AS; Au-Yeung A; Takahashi C; O'Gorman WE; Wu TD; Mittman S; Cubas R; Comps-Agrar L; Fulzele A; Bennett EJ; Grogan JL; Hui E; Chiang EY; Mellman I
Immunity; 2022 Mar; 55(3):512-526.e9. PubMed ID: 35263569
[TBL] [Abstract][Full Text] [Related]
5. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J
Front Immunol; 2021; 12():699895. PubMed ID: 34367161
[TBL] [Abstract][Full Text] [Related]
6. Anti-TIGIT therapies for solid tumors: a systematic review.
Rousseau A; Parisi C; Barlesi F
ESMO Open; 2023 Apr; 8(2):101184. PubMed ID: 36933320
[TBL] [Abstract][Full Text] [Related]
7. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
8. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
[TBL] [Abstract][Full Text] [Related]
9. TIGIT in cancer immunotherapy.
Chauvin JM; Zarour HM
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900861
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint targeting TIGIT in hepatocellular carcinoma.
Zheng Q; Xu J; Gu X; Wu F; Deng J; Cai X; Wang G; Li G; Chen Z
Am J Transl Res; 2020; 12(7):3212-3224. PubMed ID: 32774695
[TBL] [Abstract][Full Text] [Related]
11. Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.
Siebert N; Zumpe M; Schwencke CH; Biskupski S; Troschke-Meurer S; Leopold J; Zikoridse A; Lode HN
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444427
[TBL] [Abstract][Full Text] [Related]
12. Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
Zhang P; Liu X; Gu Z; Jiang Z; Zhao S; Song Y; Yu J
Biomark Res; 2024 Jan; 12(1):7. PubMed ID: 38229100
[TBL] [Abstract][Full Text] [Related]
13. Higher TIGIT
Jin Z; Lan T; Zhao Y; Du J; Chen J; Lai J; Xu L; Chen S; Zhong X; Wu X; Li Y
Immunol Invest; 2022 Jan; 51(1):40-50. PubMed ID: 32819181
[TBL] [Abstract][Full Text] [Related]
14. Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced effector functions in dermatomyositis.
Li W; Deng C; Yang H; Lu X; Li S; Liu X; Chen F; Chen L; Shu X; Zhang L; Liu Q; Wang G; Peng Q
Arthritis Res Ther; 2021 Jan; 23(1):15. PubMed ID: 33413573
[TBL] [Abstract][Full Text] [Related]
15. Targeting novel inhibitory receptors in cancer immunotherapy.
Ding QQ; Chauvin JM; Zarour HM
Semin Immunol; 2020 Jun; 49():101436. PubMed ID: 33288379
[TBL] [Abstract][Full Text] [Related]
16. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
[TBL] [Abstract][Full Text] [Related]
17. Perturbed CD8
Tauriainen J; Scharf L; Frederiksen J; Naji A; Ljunggren HG; Sönnerborg A; Lund O; Reyes-Terán G; Hecht FM; Deeks SG; Betts MR; Buggert M; Karlsson AC
Sci Rep; 2017 Jan; 7():40354. PubMed ID: 28084312
[TBL] [Abstract][Full Text] [Related]
18. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade.
Ma L; Gai J; Qiao P; Li Y; Li X; Zhu M; Li G; Wan Y
Biochem Biophys Res Commun; 2020 Oct; 531(2):144-151. PubMed ID: 32782142
[TBL] [Abstract][Full Text] [Related]
19. Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.
Boissière-Michot F; Chateau MC; Thézenas S; Guiu S; Bobrie A; Jacot W
Front Immunol; 2022; 13():1058424. PubMed ID: 36544779
[TBL] [Abstract][Full Text] [Related]
20. Expression of the immune checkpoint receptor TIGIT in seminoma.
Hinsch A; Blessin NC; Simon R; Kluth M; Fischer K; Hube-Magg C; Li W; Makrypidi-Fraune G; Wellge B; Mandelkow T; Debatin NF; Höflmayer D; Lennartz M; Sauter G; Izbicki JR; Minner S; Büscheck F; Uhlig R; Dum D; Krech T; Luebke AM; Wittmer C; Jacobsen F; Burandt E; Steurer S; Wilczak W
Oncol Lett; 2019 Aug; 18(2):1497-1502. PubMed ID: 31423216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
